Key facts
- Ruoyi Bio’s last known valuation is $23.4M (Mar 2022).
- It has raised $7.6M; the latest was Later Stage VC in Mar 2026.
- Notable investors include YuanBio Venture Capital, Kunshan Industrial Technology Research Institute, Kunshan Guoke Venture Capital, Alan Asset Management, DNE Group.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Ruoyi Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Ruoyi Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ruoyi Bio
Developer of recombinant protein drug intended for synthetic biology. The company offers capabilities in drug discovery and biopharmaceutical development, Zinc finger protein drug delivery technology, recombinant botulinum toxin drug pipeline, and Insect cell-baculovirus platform, enabling an AI-based protein transformation project and new vitality into corporate development.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Employees
- 14
- Website
- asiflyerbio.com/
- Ownership
- Privately Held (backing)
Ruoyi Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ruoyi Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ruoyi Bio in its N-PORT filings yet. We sweep new filings monthly.